Bernard-Soulier Syndrome Does NOT Respond to Steroids
Bernard-Soulier syndrome (BSS) is a genetic platelet disorder that does not respond to corticosteroid therapy, and steroids should not be used as treatment. This is a critical distinction from immune thrombocytopenic purpura (ITP), which BSS frequently mimics and is often misdiagnosed as 1, 2, 3.
Why Steroids Don't Work in BSS
BSS is caused by mutations in genes encoding the glycoprotein Ib-IX-V complex (GP1BA, GP1BB, or GP9), resulting in a structural platelet defect 1, 3. This is fundamentally different from ITP, which is an autoimmune condition where steroids suppress antibody production against platelets.
The pathophysiology of BSS involves:
- Absent or deficient platelet surface glycoprotein expression
- Macrothrombocytopenia (large platelets with low counts)
- Impaired platelet adhesion and function
- Autosomal recessive inheritance in most cases 3
Since the problem is genetic and structural—not immune-mediated—immunosuppressive therapy including steroids has no mechanism to correct the underlying defect.
Clinical Evidence of Steroid Ineffectiveness
Multiple case reports document the failure of corticosteroids in BSS:
- A 68-year-old patient misdiagnosed with von Willebrand disease for 30 years received corticosteroids for gastrointestinal bleeding, which were completely ineffective 1
- A case series of seven BSS patients misdiagnosed as ITP were treated with steroids, IVIG, anti-D, and other immunosuppressive agents—all without benefit 2
- These patients only achieved proper management after genetic testing confirmed BSS and treatment shifted to platelet transfusions 2
Critical Diagnostic Pitfall
The most dangerous aspect of BSS is its frequent misdiagnosis as ITP, leading to inappropriate steroid therapy 2, 3. This misdiagnosis occurs because both conditions present with:
- Thrombocytopenia
- Mucocutaneous bleeding
- Normal or increased bone marrow megakaryocytes
Key distinguishing features that should prompt consideration of BSS rather than ITP:
- Giant platelets on blood smear (macrothrombocytopenia)
- Consanguineous parents or family history of thrombocytopenia 2
- Persistent thrombocytopenia unresponsive to ITP treatments
- Absent ristocetin-induced platelet aggregation
- Reduced or absent GPIb expression on flow cytometry (<10%) 2
- Bleeding symptoms from early childhood 3
Appropriate Management of BSS
The mainstay of treatment for BSS is platelet transfusion 3. Additional therapeutic options include:
- Platelet transfusions: Primary therapy for acute bleeding
- Recombinant factor VIIa: For patients who develop alloimmunization to platelets 3
- Antifibrinolytics: Supplementary therapy for mucosal bleeding
- Oral contraceptives: For menorrhagia management 3
- Allogeneic stem cell transplantation: Reserved for refractory cases 3
One older anesthesia case report from 2004 mentioned considering corticosteroids as a "potential benefit" 4, but this was speculative and not supported by evidence. More recent comprehensive reviews make no mention of steroids as effective therapy 3.
The Exception: Acquired BSS-Like Syndrome
There is one documented case of acquired (not congenital) BSS-like syndrome due to an autoantibody that responded to rituximab 5. However, this represents an entirely different disease mechanism—an acquired autoimmune condition mimicking BSS—not true genetic BSS.
Bottom line: If a patient with apparent BSS responds to steroids, the diagnosis is wrong. The patient likely has ITP or another immune-mediated condition, and genetic testing should be pursued to establish the correct diagnosis 1, 2.